Here’s Who Just Picked Up Entellus Medical Inc. (NASDAQ:ENTL) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Entellus Medical Inc. (NASDAQ:ENTL) reported that Discovery Group I, Llc. has picked up 1,418,715 of common stock as of 2017-03-06.
The acquisition brings the aggregate amount owned by Discovery Group I, Llc. to a total of 1,418,715 representing a 6.5% stake in the company.
For those not familiar with the company, Entellus Medical, Inc. is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation. The Company’s XprESS family of products is used to treat patients with inflammation of the frontal, ethmoid, sphenoid and maxillary sinuses. Its XprESS Multi-Sinus Dilation family of products consists of its XprESS Pro device, its XprESS LoProfile device and its XprESS Ultra device. The Company’s PathAssist tools provide ENT physicians with a way to confirm sinus location and XprESS device placement. Its FocESS Sinuscopes provide ENT physicians with a solution for endoscopic visualization during a sinus procedure.
A glance at Entellus Medical Inc. (NASDAQ:ENTL)’s key stats reveals a current market capitalization of 286.30 million based on 21.88 Million shares outstanding and a price at last close of $13.32 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-02-03, Split picked up 352,941 at a purchase price of $17.00. This brings their total holding to 3,156,731 as of the date of the filing.
On the sell side, the most recent transaction saw Essex unload 16,521 shares at a sale price of $17.00. This brings their total holding to 91,808.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Entellus Medical Inc. (NASDAQ:ENTL) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Ashford Hospitality Prime Inc. (CVE:AHP) is Attracting Smart Money
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Ashford Hospitality Prime Inc. (CVE:AHP) reported that Raging Capital Management has picked up 3,161,180 of common stock as of 2017-03-06.
The acquisition brings the aggregate amount owned by Raging Capital Management to a total of 3,161,180 representing a 4.2% stake in the company.
For those not familiar with the company, Ashford Hospitality Prime, Inc. invests in high revenue per available room (RevPAR), luxury, upper-upscale and upscale hotels in gateway and resort locations. The Company conducts its business and owns all of its assets through its operating partnership, Ashford Hospitality Prime Limited Partnership. It operates in the direct hotel investment segment of the hotel lodging industry. It owns interest in over 15 hotels in approximately six states, the District of Columbia and St. Thomas, the United States Virgin Islands with over 3,950 total rooms, excluding those attributable to its partner. The hotels in its portfolio are located in the United States gateway and resort locations. The Company owns over 10 of its hotel properties directly, and the remaining hotel properties through an investment in a majority-owned consolidated entity. All of the hotels in the Company’s portfolio are asset-managed by Ashford Hospitality Advisors LLC.
A glance at Ashford Hospitality Prime Inc. (CVE:AHP)’s key stats reveals a current market capitalization of 287.49 million based on 26.03 Million shares outstanding and a price at last close of $11.05 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2014-06-06, Rinaldi picked up 800 at a purchase price of $16.87. This brings their total holding to 8,000 as of the date of the filing.
On the sell side, the most recent transaction saw Kessler unload 2,441 shares at a sale price of $15.00. This brings their total holding to 101,294.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Ashford Hospitality Prime Inc. (CVE:AHP) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Cpmg Inc. Picked Up Reata Pharmaceuticals Inc. (NASDAQ:RETA) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported that Cpmg Inc. has picked up 3,161,180 of common stock as of 2017-03-06.
The acquisition brings the aggregate amount owned by Cpmg Inc. to a total of 3,161,180 representing a 20.9% stake in the company.
For those not familiar with the company, Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company’s lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich’s ataxia, mitochondrial myopathies and metastatic melanoma.
A glance at Reata Pharmaceuticals Inc. (NASDAQ:RETA)’s key stats reveals a current market capitalization of 659.60 million based on 22.34 Million shares outstanding and a price at last close of $28.14 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-12-30, Traweek picked up 9,392 at a purchase price of $21.72. This brings their total holding to 1,926,034 as of the date of the filing.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Reata Pharmaceuticals Inc. (NASDAQ:RETA) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Guess Who Picked Up Optimizerx Corp (OTCMKTS:OPRX) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Optimizerx Corp (OTCMKTS:OPRX) reported that Wolverine Asset Management Llc. has picked up 2,155,860 of common stock as of 2017-03-06.
The acquisition brings the aggregate amount owned by Wolverine Asset Management Llc. to a total of 2,155,860 representing a 7.3% stake in the company.
For those not familiar with the company, OptimizeRx Corporation is a technology solutions company. The Company focuses on the healthcare industry. The Company connects patients, physicians and pharmaceutical manufacturers through technology. The Company’s solutions provide pharmaceutical manufacturers a direct to physician channel for communicating and promoting products. It provides healthcare providers a means to provide sampling and coupons without having to physically store samples on site. The Company’s principal products and applications include SampleMD, OPTIMIZEHR and OPTIMIZERx.com. SampleMD is a virtual Patient Support Center. OPTIMIZEHR is a consulting practice focused on educating and working with pharmaceutical manufacturers on identifying, formulating and implementing new electronic prescribing (eRx) media strategies for promoting their products. OPTIMIZERx.com is a portal to healthcare savings for patients to centrally review and participate in prescription and healthcare savings and support programs.
A glance at Optimizerx Corp (OTCMKTS:OPRX)’s key stats reveals a current market capitalization of 23.84 million based on 29.67 Million shares outstanding and a price at last close of $0.750 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-12-13, Pinney picked up 4,000 at a purchase price of $0.80. This brings their total holding to 781,079 as of the date of the filing.
On the sell side, the most recent transaction saw Radoff unload 631,100 shares at a sale price of $1.41. This brings their total holding to 2,289,200.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Optimizerx Corp (OTCMKTS:OPRX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Bok Financial Corp Et Al (NASDAQ:BOKF) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Bok Financial Corp Et Al (NASDAQ:BOKF) reported that George Kaiser Family Foundation has picked up 2,714,286 of common stock as of 2017-03-06.
The acquisition brings the aggregate amount owned by George Kaiser Family Foundation to a total of 2,714,286 representing a 4.14% stake in the company.
For those not familiar with the company, BOK Financial Corporation is a financial holding company. The Company offers full service banking in Oklahoma, Texas, New Mexico, Colorado, Arizona and Kansas/Missouri. Its segments include Commercial Banking, Consumer Banking, Wealth Management, and Funds Management and Other. The Commercial Banking segment includes lending, treasury and cash management services, and customer risk management products for small businesses, middle market and commercial customers. The Consumer Banking segment includes retail lending and deposit services, lending and deposit services to small business customers served through the retail branch network and all mortgage banking activities. The Wealth Management segment provides fiduciary services, private bank services and investment advisory services in all markets; underwrites state and municipal securities, and engages in brokerage and trading activities. The Funds Management unit manages overall liquidity needs and interest rate risk.
A glance at Bok Financial Corp Et Al (NASDAQ:BOKF)’s key stats reveals a current market capitalization of 5.48 billion based on 65.49 Million shares outstanding and a price at last close of $83.20 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2014-09-04, Walker picked up 3,650 at a purchase price of $67.88. This brings their total holding to 3,670 as of the date of the filing.
On the sell side, the most recent transaction saw Nell unload 333 shares at a sale price of $83.30. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Bok Financial Corp Et Al (NASDAQ:BOKF) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Whiting Petroleum Corp (NYSE:WLL) is Attracting Smart Money
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Whiting Petroleum Corp (NYSE:WLL) reported that Senator Investment Group has picked up 21,500,000 of common stock as of 2017-03-06.
The acquisition brings the aggregate amount owned by Senator Investment Group to a total of 21,500,000 representing a 5.93% stake in the company.
For those not familiar with the company, Whiting Petroleum Corporation is an independent oil and gas company. The Company is engaged in development, production, acquisition and exploration activities primarily in the Rocky Mountains and Permian Basin regions of the United States. The Company operates in the segment of exploration and production of crude oil, natural gas liquid (NGLs) and natural gas. The Company’s estimated proved reserves totaled approximately 820.6 Million Barrels of Oil Equivalent (MMBOE). The Company has interests in approximately 5,889 gross (3,177 net) productive wells on approximately 948,600 gross (593,900 net) developed acres across all its geographical areas. The Company’s Rocky Mountains operations include assets in the states of Colorado, Montana and North Dakota. The Company’s Permian Basin operations include its North Ward Estes field in the Ward and Winkler counties of Texas. Its other operations primarily relate to non-core assets in Colorado, Mississippi, North Dakota, Texas and Wyoming.
A glance at Whiting Petroleum Corp (NYSE:WLL)’s key stats reveals a current market capitalization of 3.88 billion based on 362.70 Million shares outstanding and a price at last close of $10.70 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-05-03, Volker picked up 10,000 at a purchase price of $10.30. This brings their total holding to 629,514 as of the date of the filing.
On the sell side, the most recent transaction saw Peterson unload 4,928 shares at a sale price of $19.67. This brings their total holding to 658,882.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Whiting Petroleum Corp (NYSE:WLL) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
D E Shaw is Buying Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) reported that D E Shaw has picked up 3,707,857 of common stock as of 2017-03-06.
The acquisition brings the aggregate amount owned by D E Shaw to a total of 3,707,857 representing a 5.0% stake in the company.
For those not familiar with the company, BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its drug candidates include RAPIVAB, RAPIACTA, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, BCX4430 and Forodesine. Its product RAPIVAB contains peramivir. Peramivir is an intravenous neuraminidase inhibitor approved in various countries for the treatment of patients with influenza, in the United States as RAPIVAB. RAPIVAB is used for the treatment of acute uncomplicated influenza. Its BCX4430 is a broad-spectrum antiviral (BSAV) research program.
A glance at Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX)’s key stats reveals a current market capitalization of 597.06 Million based on 73.96 Million shares outstanding and a price at last close of $7.80 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-02-05, Baker picked up 45,000 at a purchase price of $6.33. This brings their total holding to 12,894,240 as of the date of the filing.
On the sell side, the most recent transaction saw Staab unload 3,250 shares at a sale price of $7.45. This brings their total holding to 124,187.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Gazit-globe Ltd. Picked Up Regency Centers Corp (NYSE:REG) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Regency Centers Corp (NYSE:REG) reported that Gazit-globe Ltd. has picked up 19,695,453 of common stock as of 2017-03-06.
The acquisition brings the aggregate amount owned by Gazit-globe Ltd. to a total of 19,695,453 representing a 11.6% stake in the company.
For those not familiar with the company, Regency Centers Corporation is a real estate investment trust (REIT) and the general partner of the Regency Centers, L.P. (Operating Partnership). The Company’s operating, investing and financing activities are performed through the Operating Partnership, its subsidiaries and through its co-investment partnerships. The Company owns direct or partial interests in approximately 320 shopping centers, which are grocery-anchored community and neighborhood centers. The Company’s centers are located in over 30 states and the District of Columbia, and contain approximately 38.0 million square feet of gross leasable area (GLA). The Company’s properties are leased to tenants under operating leases. Its leases for tenant space under approximately 5,000 square feet have terms ranging from three to five years. The Company’s leases over 10,000 square feet have lease terms in excess of five years, which consists of anchor tenants.
A glance at Regency Centers Corp (NYSE:REG)’s key stats reveals a current market capitalization of 6.84 Billion based on 104.70 Million shares outstanding and a price at last close of $66.63 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-12-22, Blair picked up 1,486 at a purchase price of $66.92. This brings their total holding to 2,737 as of the date of the filing.
On the sell side, the most recent transaction saw Katzman unload 750,000 shares at a sale price of $68.45. This brings their total holding to 4,115,540.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Regency Centers Corp (NYSE:REG) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.